Shamburg News · 8-K filed Nov 16, 2026, 8:08 AM EST
Iambic Therapeutics Reports Third Quarter 2026 Results and Business Updates
IAM · Iambic Therapeutics, Inc.
- Earnings
- Financing
- Materiality: high
Iambic Therapeutics reported collaboration revenue of $11.4 million and a net loss of $38.5 million for the third quarter ended September 30, 2026, compared with $4.7 million and $21.5 million a year earlier. Research and development expenses were $34.1 million and general and administrative expenses were $7.4 million for the quarter. The company also reported cash and cash equivalents of $252 million as of September 30, 2026, and said its October 2026 IPO generated net proceeds of approximately $156 million.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-462184.
Written from the filing by Shamburg Markets. Figures are as reported by the company.